COVID-19：AGC Biologics 提高 RNA 生产：在其海德堡
AGC Biologics：（总部：美国）
AGC Biologics 是 AGC Biopharmacy CDMO * 业务的子公司。
提供的mRNA制造服务：
满足强劲需求。
在德国海德堡工厂
信使RNA（mRNA）的，
建立制造合同服务提供体系。
质粒 DNA (pDNA) 的生产：
我们决定扩大作为原料的质粒DNA（pDNA）生产线。
该行动计划于 2023 年年中开始。
新闻资讯｜AGC
https://www.agc.com/news/detail/1202417_2148.html
AGC Biologics to Build New Messenger RNA Capacity at its Heidelberg Facility
―With Additional Production Capacity for Plasmid-DNA, a Starting Material for Messenger RNA Production―
AGC (AGC Inc.; Headquarters: Tokyo; President: Yoshinori Hirai), a world-leading manufacturer of glass, chemicals, and high-tech materials, has announced that
its biopharmaceutical CDMO* subsidiary, AGC Biologics (United States), is expanding its Heidelberg facility to create capacity for messenger RNA (mRNA) projects,
and additional production capacity for plasmid-DNA (pDNA), which one of its uses is as material for mRNA production.
This expansion
will enable AGC Biologics to better service the needs of the growing pDNA and mRNA global markets.
The facility’s new capabilities
will be fully operational in around mid-2023.
In addition to this expansion,
AGC Biologics
is expanding its cell and gene therapy capacity at the Milan site
and has acquired a cell and gene therapy manufacturing facility in Longmont, Colorado, U.S., as previously announced.
Through these investments,
AGC Biologics
is accelerating its growth as one of the few CDMOs in the world that can provide integrated end-to-end services for the manufacture of cell and gene therapies.
News ｜ AGC
https://www.agc.com/en/news/detail/1202418_2814.html
AGC Biologics Enters Agreement to Acquire Facility in Longmont, Colorado, U.S. ｜ News ｜ AGC